Know Cancer

forgot password

San Francisco Bay Area Adult Glioma Prognosis Study Protocol

18 Years
Open (Enrolling)
Brain and Central Nervous System Tumors

Thank you

Trial Information

San Francisco Bay Area Adult Glioma Prognosis Study Protocol



- Determine factors related to glioma survival in patients from two population-based case
series collected in the San Francisco Bay Area between August 1991 and April 1994
(series 1) and May 1997 and August 1999 (series 2).


- Determine vital status for 879 patients in the two San Francisco Bay Area
population-based series through July 2004.

- Determine survival as a function of established, potential, and yet unstudied
prognostic indicators.

- Gather data to validate results from this study with information from adult glioma
patients enrolled prospectively at the UCSF-Neuro-Oncology clinic and through series 3
of the San Francisco Bay Area Adult Glioma Study; incorporate results from this study
and other components of the SPORE into ongoing clinical investigations at the Brain
Tumor Research Center and Neuro-Oncology Service at UCSF.

- Using funding from the organization Accelerate Brain Cancer Cure (ABC2), genotype
several thousand single nucleotide polymorphisms (SNPs) from some study participants;
assess these SNPs for potential relationship to glioma survival.

OUTLINE: Medical records of patients registered to the California Cancer Registry or the
Northern California Cancer Center SEER are reviewed for mortality and treatment information
related to the brain tumor. Blood and buccal specimens are collected from patients with
newly diagnosed disease who are being seen at the UCSF Neuro-Oncology Service. The specimens
are used for polymporphism and tumor marker studies and other pertinent data. Tumor
specimens and treatment information related to the brain tumor are also collected from the
SPORE Tissue Core.

Additional tumor makers are studied, including: chromosome 1p/19q, 7q studies; DNA repair
and oxidative metabolism polymorphisms; and up to 2 tumor markers and 2 constitutive
genotyping studies.

Inclusion Criteria


- Diagnosis of glioma

- Meets 1 of the following criteria:

- Participant in the Survival study of San Francisco Bay Area Adult Glioma Study
(SFBAAGS) Series 1 and 2

- Treated by UCSF Neuro-Oncology Service; diagnosed between Nov. 1, 2001 and June
30, 2006 and seen between Aug. 1, 2002 and June 30, 2006

- Participant in SFBAAGS Series 3 (not seen at UCSF Neuro-Oncology Service)
diagnosed between Nov. 1, 2001 and Oct. 31, 2004


- Not specified


- Not specified

Type of Study:


Study Design:


Outcome Measure:

Factors related to glioma survival

Safety Issue:


Principal Investigator

Margaret Wrensch

Investigator Role:

Study Chair

Investigator Affiliation:

University of California, San Francisco



Study ID:




Start Date:

October 2001

Completion Date:

Related Keywords:

  • Brain and Central Nervous System Tumors
  • adult anaplastic astrocytoma
  • adult diffuse astrocytoma
  • adult pilocytic astrocytoma
  • adult subependymal giant cell astrocytoma
  • adult anaplastic ependymoma
  • adult ependymoma
  • adult myxopapillary ependymoma
  • adult subependymoma
  • adult anaplastic oligodendroglioma
  • adult oligodendroglioma
  • adult brain stem glioma
  • adult giant cell glioblastoma
  • adult glioblastoma
  • recurrent adult brain tumor
  • adult gliosarcoma
  • adult mixed glioma
  • adult pineal gland astrocytoma
  • adult ependymoblastoma
  • adult medulloblastoma
  • adult supratentorial primitive neuroectodermal tumor (PNET)
  • adult pineoblastoma
  • adult pineocytoma
  • Glioma
  • Nervous System Neoplasms
  • Central Nervous System Neoplasms



UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California  94115